For many attendees, this year’s J.P. Morgan Healthcare Conference didn’t seem to live up to its trademark frenetic energy. Last year, Bristol-Myers’ $74 billion Celgene deal announcement—which happened just days before JPM—set the biopharma world abuzz, and Lilly kept the ball rolling with its $8 billion Loxo pact on Day 1 of the meeting. But this year? Crickets.
More: Think JPM seemed slow this year? You're not alone—and here's why